AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

 AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

AstraZeneca Signs Development and Commercialization Agreement with Kyowa Hakko Kirin for its Fasenra (beralizumab)

Shots:

  • Kyowa Kirin to receives upfront, regulatory & commercial milestones. AstraZeneca to get global rights to develop & commercialize Fasenra (beralizumab) for all indication across 14 Asian countries including Japan
  • In Mar,2017 AstraZeneca & Kyowa Kirin collaborated to develop & commercialize Fasenra (beralizumab) for severe asthma and chronic obstructive pulmonary disease (COPD) in Asia
  • Fasenra (beralizumab, SC, 30mg, FD) is a mAb admninistered using prefilled syringe targeting NKcells and has received FDA’s ODD for the hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA)

Click here to read full press release/ article | Ref: Kyowa Hakko Kirin | Image: Kyowa Hakko Kirin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post